Hotline 24/7: 0909384389

Share links:

NICE recommends new treatment to reduce stroke and heart attack deaths

Ngày 27/06/2022 02:55 | Lượt xem: 564

The National Institute for Health and Care Excellence (NICE) has recommended the use of VAZKEPA (icosapent ethyl; Amarin) in adult statin-treated patients at high cardiovascular risk who have elevated triglycerides (≥150 mg/dL [≥ 1.7 mmol/L]), LDL-C levels >1.04 mmol/L (and ≤ 2.60 mmol/L) and established cardiovascular disease (CVD).1,2 The final guidance is expected to be available on 20 July 2022.

This is the first treatment in this class recommended by NICE for cardiovascular (CV) risk reduction. Icosapent ethyl is a new active substance, comprising a highly purified omega-3 fatty acid (eicosapentaenoic acid >96%). With this recommendation, icosapent ethyl has the potential to benefit more than one million people in England at high risk of a subsequent CV event, such as a second heart attack.1

More than six million people live with CVD in England, costing the NHS around £7.4 billion each year.3,4 While current therapies have helped to reduce the risk of future major CV events, more than 137,000 people continue to die from CVD each year.3 Significant future risk also remains for patients, with one in three suffering a subsequent CV event within seven years after a first heart attack episode.5

Icosapent ethyl represents an innovation in reducing this CV risk in patients in England. Evidence from the pivotal double-blind, randomised REDUCE-IT phase 3 clinical trial demonstrated, in more than 8,000 patients over an average of 4.9 years, that treatment with icosapent ethyl compared to placebo resulted in a 25% relative reduction in the risk of future major adverse CV events (a composite of CV death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation or hospitalisation for unstable angina), a 4.8% absolute risk reduction with a number needed to treat to avoid one event of 21.6

Derek Connolly, a consultant interventional cardiologist at Sandwell & West Birmingham Hospitals NHS Trust (Birmingham, UK) said: “CVD ranks as one of the UK’s leading causes of death.3 Current therapies such as statins that reduce low-density lipoprotein cholesterol (LDL-C) levels have achieved major successes in reducing deaths from CV events, but they are not a complete solution.

“Patients with a well-managed LDL-C level are still at risk of a CV event and other factors, such as elevated blood triglycerides, should be considered as a risk marker for future events. The REDUCE-IT trial demonstrated that with icosapent ethyl it is possible to reduce this this risk further, helping to prevent future CV events.”

The most frequently reported adverse reactions in the REDUCE-IT trial associated with icosapent ethyl were bleeding (11.8%), peripheral oedema (7.8%), atrial fibrillation (5.8%), constipation (5.4%), musculoskeletal pain (4.3%), gout (4.3%) and rash (3.0%).2

Amarin’s senior vice president and president of Europe, Laurent Abuaf, added: “VAZKEPA offers an important scientific innovation for patients with CVD, and the results of the REDUCE-IT trial demonstrate the benefits of its use for optimising the outcomes of patients at high risk of CV events, on top of treatments for traditional risk factors.

“NICE’s recommendation will help to reduce the risk of CV events amongst a significant number of patients across England and Wales, and we are committed to working with all relevant stakeholders in the NHS to offer this important new treatment option to patients with CVD.”

Source CardiovascularNews

Duc Tin CLinic

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

CUSTOMER REVIEWS

• I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

  I sincerely thank you !. Tel: 0938303275

• Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

  Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

• As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

• The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

• I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search

News

Customer support